Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
CNBC Stocks· Nov 6, 2026 · 11:56 AM
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
This is a summary. Read the complete story at CNBC Stocks below.
Read full article at CNBC StocksRelated Stories
stocksabout 2 hours ago
Nasdaq futures rise as AI rout pauses amid dip buying
Investing.com
stocksabout 2 hours ago
Premarket movers: Airbnb, Cloudflare, IREN rally; Atlassian, Five9 tumble
Investing.com
stocksabout 2 hours ago
Nasdaq futures rise after steep AI selloff as chip stocks stabilize
Investing.com